DePuy Synthes Spine, Biomaterials Granted Exclusive Right to Market Cellular Allograft Product

DePuy Synthes Spine and DePuy Synthes Biomaterials have gained the exclusive worldwide rights to market LifeNet Health’s cellular allograft product.

Advertisement

This agreement is DePuy Synthes Spine’s first move into cellular allografts for spinal fusion.

LifeNet Health is a developer of allograft bioimplants and cellular therapies.

More Articles on Devices:
Texas Hospital Purchases Second Renaissance Spine System From Mazor Robotics
Smith & Nephew to Purchase ArthroCare for $1.7B
Global Medical Device Market to Reach $434.4B by 2017

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.